MapLight Therapeutics (MPLT) EPS (Basic) (2024 - 2026)
MapLight Therapeutics (MPLT) posted EPS (Basic) of -$9.35 for Q4 2025, up 78.28% sequentially from -$43.06 in Q3 2025, and up 68.08% YoY from -$5.57 in Q4 2024.
MapLight Therapeutics (MPLT) EPS (Basic) (2024 - 2026) Analysis & Trends
MapLight Therapeutics has reported EPS (Basic) for 2 years, with the latest figure at -$9.35 in Q4 2025.
- Quarterly EPS (Basic) rose 68.08% year-over-year to -$9.35 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$18.08 (changed N/A YoY) and the FY2025 annual result came in at -$20.3, up 83.57% from the prior year.
- EPS (Basic) climbed to -$9.35 in Q4 2025 per MPLT's latest filing, from -$43.06 in the prior quarter.
- Over five years, EPS (Basic) peaked at -$9.35 in Q4 2025 and troughed at -$43.06 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Basic) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 4.34 |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 12.62 |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 7.59 |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -3.06 |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 0.16 |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 0.00 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 0.18 |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.23 |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -0.06 |
| 10 | MapLight Therapeutics | 533.88 Mn | 533.88 Mn | - | -3.35 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -3.35 |
| Dec 31, 2025 | -9.35 |
| Sep 30, 2025 | -43.06 |
| Dec 31, 2024 | -29.31 |
| Sep 30, 2024 | -26.53 |